Parathyroid hormone (PTH) is central to calcium homeostasis and bone maintenance in vertebrates, and as such it has been used for treating osteoporosis. It acts primarily by binding to its receptor, PTH1R, a member of the class B G protein-coupled receptor (GPCR) family that also includes receptors for glucagon, calcitonin, and other therapeutically important peptide hormones. Despite considerable interest and much research, determining the structure of the receptor-hormone complex has been hindered by difficulties in purifying the receptor and obtaining diffraction-quality crystals. Here, we present a method for expression and purification of the extracellular domain (ECD) of human PTH1R engineered as a maltose-binding protein (MBP) fusion that readily crystallizes. The 1.95-Å structure of PTH bound to the MBP-PTH1R-ECD fusion reveals that PTH docks as an amphipathic helix into a central hydrophobic groove formed by a three-layer ␣-␤-␤␣ fold of the PTH1R ECD, resembling a hot dog in a bun. Conservation in the ECD scaffold and the helical structure of peptide hormones emphasizes this hot dog model as a general mechanism of hormone recognition common to class B GPCRs. Our findings reveal critical insights into PTH actions and provide a rational template for drug design that targets this hormone signaling pathway.
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calcitonin ͉ crystal structure ͉ glucagon ͉ maltose-binding protein ͉ osteoporosis P arathyroid hormone (PTH) is a classic endocrine hormone that was first identified more than 80 years ago as a key regulator of blood calcium levels (1) (2) (3) . Decades of research have established PTH as a major systemic hormone that controls mineral ion homeostasis and bone maintenance (4, 5) . In response to either low calcium or high phosphate levels in the circulation, PTH is synthesized and secreted into the bloodstream as an 84-amino acid polypeptide from the chief cells of the parathyroid glands (6, 7) . The primary actions of PTH occur in kidney and bone tissues. In kidney, PTH promotes renal tubular calcium resorption and synthesis of 1,25-dihydroxyvitamin D 3 but prevents resorption of phosphate (8) . In bone, PTH increases osteoclastic bone resorption as part of calcium homeostasis, and the stimulatory effects of PTH on osteoblasts increase bone mass (9) . Daily administration of PTH, or its N-terminal 34-residue fragment PTH-(1-34), enhances bone formation and increases bone density in patients with osteoporosis (10, 11) . Both versions of PTH have been used in clinics as a treatment for osteoporosis in recent years, which has provided a major push for research programs on PTH as related to bone and mineral ion homeostasis. Notably, the activation of PTH signaling in osteoblast cells is also critical in providing an environmental niche for the maintenance of hematopoietic stem cells in bone marrow (12) .
The pleiotropic effects of PTH are mediated primarily through the binding and activation of the PTH receptor (PTH1R), which is highly expressed in PTH target tissues (13) . PTH also binds to a second receptor (PTH2R) with a distinct pharmacology (for review, see ref. 14) . Both PTH receptors belong to the class B G protein-coupled receptors (GPCRs). As a class B GPCR, PTH1R contains an N-terminal extracellular domain (ECD) with three conserved disulfide bonds and a C-terminal domain with seven transmembrane helices. In addition to PTH, PTH1R also recognizes PTH-related peptide (PTHrP), a paracrine/autocrine factor originally discovered in many tumors that causes the syndrome of malignancy-associated hypercalcemia (15) (16) (17) (18) . PTHrP is developmentally regulated and expressed, and it has been shown to play a vital role in bone formation during embryogenesis (19) .
There exists a large body of data regarding the structurefunction relationships of PTH and PTHrP and their binding to PTH1R, a consequence of the pervasive role of these molecules in bone maintenance and their therapeutic applications for osteoporosis (for review, see ref. 20) . The N-terminal 34-residue fragments of PTH and PTHrP [PTH- and PTHrP-(1-34)] are capable of fully activating the receptors to the same degree as the full-length PTH and PTHrP-(1-141) (21, 22) . NMR studies reveal that PTH-(1-34) and PTHrP-(1-34) share a similar U-shaped tertiary structure (23, 24) , whereas the x-ray crystal structure of PTH-(1-34) shows a single continuous helix (25) . Studies with ligand variants and receptor/ligand photo cross-linking indicate that the Nterminal fragment of PTH (residues 1-14) binds to the transmembrane domain, albeit with low affinity, and that it is able of activating the receptor (26, 27) . The C-terminal fragment of PTH (residues 15-34) binds to the N-terminal ECD of the receptor to confer high affinity and specificity to the receptor (28, 29) . This ''two-domain'' model of PTH binding and activation is further supported by studies with chimeric ligands and receptors (30) (31) (32) and has since been demonstrated for other class B GPCR molecules (33) (34) (35) .
In addition to PTH receptors, the family of class B GPCRs also includes receptors for glucagon, glucagon-like peptides (GLPs), glucose-dependent insulinotropic polypeptide (GIP), calcitonin, growth hormone-releasing hormone, corticotropin-releasing factor (CRF), and other therapeutically important peptides hormones (36) . Given the pharmaceutical importance of these receptors, there has been intensive interest in elucidating the structure of their hormone-bound complexes. However, these efforts have been hampered by technical difficulties in purifying soluble and functional proteins in the large quantities required for structural studies. Very recently, the structures of the receptor ECD-ligand complexes have been reported for the murine CRF receptor 2␤ (CRFR2␤) and the human GIPR (37, 38) . These structures reveal a similar scaffold of two antiparallel ␤-sheets, resembling a short consensus repeat (SCR) fold found in immunoglobins (37, 38) . Except for a few core residues that form the conserved SCR fold, the ECD of PTH1R shares little sequence homology with that of CRFR2␤ and GIPR. Thus, a detailed understanding of PTH binding and activation of PTH1R requires a high-resolution structure of a PTH1R receptor-ligand complex.
In this work, we present a general methodology that we developed for expression and purification of the ECD of class B GPCRs, which allowed us to crystallize and solve the PTH-PTH1R ECD structure at 1.95-Å resolution. The structure reveals a ''hot dog'' model of PTH binding, in which PTH is docked as a straight helix into the central groove of a three-layer fold adopted by the receptor. The detailed interactions from this structure provide an explanation for the binding specificity of PTH to PTH1R and a rational template for optimizing PTH derivatives for therapeutic applications.
Results and Discussion
General Method for Expression, Purification, and Crystallization of the ECD of Class B GPCRs. For structural studies of the peptide hormonereceptor ECD complex, we aimed to develop a general method for bacterial expression and purification of the PTH1R ECD that is applicable to all class B GPCRs. This method has five key features (Fig. 1A) . First, the PTH1R ECD was fused with the bacterial maltose-binding protein (MBP) at the N terminus to increase protein solubility because MBP is able to improve the stability of the fusion proteins (39) . Second, the MBP-PTH1R-ECD fusion contains a C-terminal hexahistidine tag. The inclusion of affinity tags at both ends of the PTH1R ECD ensures purification of the full-length product. Third, the fusion protein was produced in a bacterial strain with mutations in the gor and trxB genes (40) , which creates an oxidized cytoplasm to facilitate disulfide bond formation within the PTH1R ECD. We used the same bacterial strain to produce a correctly folded hepatocyte growth factor NK1 fragment, which contains five disulfide bonds (41) . Fourth, the fusion protein was coexpressed with DsbC (40), a bacterial disulfide isomerase, which has chaperone activity to further promote correct folding and disulfide bond formation. Despite coexpression with DsbC, much of the ECD was misfolded, as evidenced by the presence of high-molecular-weight species on a nonreducing denaturing gel (lane 1 in The functional activity of the purified protein was assessed by its direct binding to PTH as determined by AlphaScreen assays and isothermal titration calorimetry (ITC). In the AlphaScreen assays, biotinylated PTH was attached to streptavidin-coated donor beads, and the MBP-PTH1R-ECD was attached to nickel-chelate-coated acceptor beads via the C-terminal His 6 tag. Incubation of PTH and the purified MBP-PTH1R ECD produced a dose-dependent binding signal, suggesting their direct interaction (Fig. 1C) . The affinity of PTH binding to the PTH1R ECD was 1-3 M, as determined by competition with an unlabeled PTH (Fig. 1D ) or by isothermal titration calorimetry (Fig. 1E ). This affinity is comparable with that of other peptide hormones for their cognate class B GPCR ECDs (37, 38) . The purified MBP-PTH1R-ECD readily produced diffraction-quality crystals in complex with a synthetic PTH fragment (residues 15-34), as described in Methods. A similar protocol was also used successfully to produce protein and crystals of the ECD of the human CRFR1, suggesting that the methodology we derived above is applicable to other class B GPCRs (unpublished results).
The key features of our method are that the targeted protein is affinity-tagged at both ends to ensure the purification of the intact protein and a disulfide-bond shuffling system that does not involve any denaturing/refolding steps. Furthermore, the MBP tag is particularly suitable for crystallization, as successfully demonstrated by a number of fusion proteins for which MBP is critical for crystal packing (42) . In our crystals, the MBP tag is also essential for the high quality of the crystals by mediating extensive contacts with the PTH1R ECD or with MBP itself [supporting information (SI) Fig.  S1 ]. The key components of this expression system are flexible, so that our method should be generally applicable to protein produc- tion and crystallization of other cell surface receptors or their ligands that contain disulfide bonds.
Overall Structure of the PTH1R ECD Bound to PTH. The crystals containing the MBP-PTH1R-ECD fusion protein bound to PTH-(15-34) formed in the P2 1 space group with two complexes in each asymmetry unit. The structure was solved by molecular replacement using the MBP structure and refined to an R factor of 18.6% at 1.95-Å resolution (43, 44) (Table S1 ). The PTH1R ECD residues 56-105 and 175-187 of molecule A and residues 58-104 and 176-187 of molecule B were excluded from the final model because of disorder. The two ECD-PTH complexes are very similar as indicated by the rmsd of their C ␣ atom positions of 0.275 Å; thus, we confine our description of the structure to the complex with molecule B. In the structure, the PTH1R ECD contains two ␣-helices and four ␤-strands, and PTH adopts a single continuous helix ( Fig. 2A) . From the front view, the secondary structure elements of the PTH1R ECD are arranged into a three-layer ␣-␤-␤␣ fold with approximate dimensions of 40 Å ϫ 25 Å ϫ 10 Å (Fig. 2C) . The top layer is an extended ␣-helix formed by the N-terminal portion of the PTH1R ECD (residues 33-57). The middle layer is divided into two halves: the left half is formed by a ␤-hairpin of the first two ␤-strands (residues 110-120), and the right half is formed by the extended turn of ␤-strands 3 and 4 (residues 130-140). The bottom layer is formed by ␤-strands 3 and 4, ␣2, and the loop connecting ␤4 to ␣2. From a side view, the thickness of the PTH1R ECD is only Ϸ10 Å (Fig. 2B) . The thinness of the PTH1R ECD suggests that it cannot form a large hydrophobic core sufficient to stabilize the ECD structure. Thus, the overall structure of the PTH1R ECD is primarily held together by three interlayer disulfide bonds (Fig. 2C) : the first (C48-C117) links the top N-terminal helix to the middle layer ␤-sheet, the second (C108-C148) links the middle and the bottom ␤-sheets, and the third (C131-C170) links the middle layer ␤-turn of strands 3 and 4 with the C-terminal ␣-helix at the bottom.
The topological arrangement of the PTH1R ECD is further supported by interlayer hydrophobic packing interactions centering on the middle ␤-hairpin and the extended turn of ␤-strands 3 and 4 (Fig. 2D) . The most prominent interactions consist of a series of stepwise packing interactions, starting with the C108-C148 disulfide bond at the left, followed by W154, R146, W118, Y167, the C131-C170 disulfide bond, L116, P132, F138, and I135 to the right Cyan indicates residues that are invariant, magenta indicates residues that have conservative substitutions, and green indicates residues that are not conserved. Hydrogen bonds are depicted as red dashes, and the red sphere is a water molecule. (E) Sequence alignment of human class B GPCR ECDs with the secondary structural elements noted over the sequences. Invariant residues are shown in white lettering on a red background, and conservative substitutions are shown in red lettering. (Fig. 2D) . These interactions help to hold the structure of the middle and the bottom layers, which are further strengthened by a series of interlayer H-bonds involving E111, D113, W118, R46, and W154. Residues involved in these interactions are mostly conserved among class B GPCRs, including D113, W118, P132, W154, and the six invariant cysteine residues (Fig. 2E) . These residues constrain the bottom two ␤-sheets into a fold that resembles the short consensus repeat, a small protein-binding module found in the immunoglobin superfamily and in the ECDs of class B GPCRs (37, 45) . Interestingly, mutation of P132 to a leucine in human PTH1R causes Blomstrand chondrodysplasia, a lethal genetic disorder (46) , suggesting that the integrity of these interactions is important for PTH-PTH1R signaling.
Structural Basis for the Binding and Specificity of PTH to PTH1R. PTH binds to the PTH1R ECD as a single amphipathic ␣-helix that docks into an extended hydrophobic groove formed by the centerright half of the ECD domain ( Fig. 3 A and B) . In this mode of PTH binding, the PTH helix resembles a hot dog sitting between the two outer layers (the bun) of the three-layer ECD (Fig. 2 A and B) . The binding of PTH to PTH1R ECD buries a solvent-accessible area of Ϸ1,900 Å 2 . The center of the PTH-binding groove is formed by the tip of the ␤-hairpin and the extended ␤-turn in the middle layer, and the top and the bottom ridges of the groove are formed by the Nand C-terminal helices, respectively. The PTH helix is approximately antiparallel to the C-terminal helix of the ECD such that the N terminus of PTH is predicted to orient toward the transmembrane domain of the full-length receptor, consistent with the two-domain model in which the PTH N-terminal residues activate the receptor.
Because of the exceptional quality of the electron density map, detailed PTH-PTH1R interactions can be clearly defined in the crystal structure (Fig. 3 C and D) . The binding of PTH to the PTH1R ECD appears to be dominated by hydrophobic interactions. Residues V21, W23, L24, L28, V31, and F34, which form an extended hydrophobic face of the PTH helix, pack closely against the central hydrophobic groove formed by the three-layer ECD fold (Fig. 3 A and B) . Notably, none of the residues that form the PTH-binding groove is conserved in class B GPCRs, suggesting a unique surface topology for each individual receptor. We examined the surface complementarity between PTH and the PTH1R ECD by using the shape correlation statistic, S c (47) . The S c value for the complex of 0.782 indicates a high degree of surface topology matching at the interface. Thus, the binding specificity of PTH to PTH1R can be determined in part by complementary shapematching between the hormone and the receptor. In addition, most of the binding groove residues are conserved between PTH1R and PTH2R, thus providing a basis to account for their similar ligandbinding specificities.
The binding of PTH to the PTH1R ECD is further strengthened by hydrogen bonds at both ends of the PTH helix (Fig. 3D) . The amidated C-terminal group forms two H-bonds with the backbone amide and carbonyl of T163. The amidated group also caps the backbone carbonyl of V31 of PTH, thus helping to stabilize the helical conformation. The C-terminal amidation is a general feature of many peptide hormones, and the hydrogen bonds described here help to explain its importance in receptor binding. The N-terminal backbone amide of PTH is capped by the PTH1R residue D30, which also forms a direct H-bond with the side chain of N16 of PTH. Most importantly, R20 of PTH forms a pair of charged interactions with D137 and two H-bonds with the backbone carbonyls of D29 and M32 of PTH1R (Fig. 3 A and D) . These polar interactions are particularly important to the binding affinity and specificity of PTH to PTH1R because R20 is completely buried within the receptor-hormone interface (Fig. 3A) . Furthermore, the residues that contact R20 are conserved in PTH1R and PTH2R but not in most other class B GPCRs, suggesting that R20 is a key determinant of ligand specificity for PTH and PTH-related ligands.
To validate the structural observations above, we examined the PTH-PTH1R interactions by alanine-scanning mutations of all PTH residues that contact PTH1R. We also chose two residues (E19 and Q29) that do not contact PTH1R as controls. As shown in Fig. 3E , addition of the wild-type unlabeled PTH inhibited Ͼ80% of the binding of biotinylated PTH to the MBP-PTH1R ECD. Replacement of any residues in the structure that contact PTH1R affected PTH binding, whereas replacement of the two control residues had little effect. In particular, replacement of the four core residues (R20, W23, L24, and L28) with alanine markedly reduced PTH binding, with mutations in the three hydrophobic residues nearly abolishing PTH binding to the ECD. Our data are in good agreement with the recent study of alanine-scanning of PTH-(17-31) (29) . These results thus further support the detailed molecular interactions observed in our crystal structure. The four core residues are well conserved in PTH, PTHrP, and TIP39 (48), a brain ligand for PTH2R, suggesting that the structure presented here can serve as a prototype for their hormonereceptor interactions (Fig. 3F) .
A Hot Dog Model for Hormone Recognition by Class B GPCRs. A common structural mechanism of hormone recognition appears to emerge from the structure comparison of the PTH-PTH1R ECD complex with two recently published structures of CRFR2␤ and GIPR (37, 38) (Fig. 4) . The bottom ␤-␤ arrangement of the SCR fold is similar in all three ECD structures. Structural alignment of the CRFR2␤ and GIPR ECDs with the PTH1R ECD yields rmsd values for their C ␣ atom positions of 2.082 Å and 1.164 Å, respectively. The arrangement of the three disulfide bonds and the packing of the hydrophobic core by key residues (D113, W118, P132, R146, and W154) are also conserved among these three hormone-receptor structures (Fig. 2E) . Although the NMR structure of the mouse CRFR2␤ ECD does not contain the N-terminal helix, our recent crystal structure of the human CRFR1 ECD reveals that it contains an N-terminal helix and a C-terminal short ␣-helix (unpublished data). Thus, the ␣-␤-␤␣ fold may represent a common structure fold adopted by the ECDs of all class B GPCRs.
Besides the common fold of the receptor ECD, the helical structure of PTH is also observed for the GIP peptide and the CRFR antagonist astressin (37, 38) . In each of these structures, the peptide helix binds the middle of the three layers of the ECD structure, resembling a hot dog, with the N-terminal helix and the C-terminal ␤-sheet serving as the top and bottom bun halves. Because the helical nature has been extensively characterized and documented for many peptide hormones (36), we propose that this hot dog model is generally applicable for ligand-receptor interactions of all class B GPCRs.
Concluding Remarks. As a classic endocrine hormone, PTH and its receptors have been the subject of intensive study over the last few decades. The high-resolution structure of PTH bound to the PTH1R ECD reveals a hot dog model of hormone recognition, in which the PTH1R ECD assumes a three-layer ␣-␤-␤␣ fold, and PTH adopts an amphipathic helix that fits into the central hydrophobic groove of the receptor ECD. The ␣-␤-␤␣ fold is conserved among class B GPCRs but is distinct from the ECD structures of class A or class C GPCRs (49, 50) , illustrating that these three families have evolved different mechanisms of hormone recognition. Because of the helical nature of peptide hormones and the conserved ␣-␤-␤␣ fold, the hot dog model of ligand recognition represents a general mechanism common to all class B GPCRs. Given its pharmaceutical importance, the PTH-PTH1R ECD structure should provide a rational template for designing better PTH mimics for the treatment of osteoporosis and hypercalcemia. Finally, the methodology that we developed is applicable for structural studies of other class B GPCRs, which will expedite our pursuit of the mechanisms of hormone recognition by these therapeutically important receptors.
Methods
Protein Production. The human PTH1R ECD [residues 29 -187, which excludes the native signal peptide (residues 1-22) (51)] was expressed as a fusion protein with MBP and His 6 tags at its N and C termini, respectively, from the expression vector pET-Duet1 in the strain Escherichia coli Origami (DE3) (Novagen), which contains trxB gor mutations that promote disulfide bond formation. Details of the plasmid construction are described in SI Methods. Cells harboring this expression plasmid were grown in LB broth to midlog phase at 37°C, cooled to 16°C, and induced with 0.4 mM IPTG for Ϸ18 h. The cells were harvested and resuspended in buffer C [50 mM Tris⅐HCl (pH 7.5), 10% (vol/vol) glycerol, 150 mM NaCl, 25 mM imidazole] and then were lysed by homogenization at 10,000 p.s.i. with an Invensys APV homogenizer (Albertslund). The lysate was centrifuged, and the supernatant was loaded on a 50-ml Ni 2ϩ -chelating Sepharose column (GE Healthcare). The column was washed with 400 ml of buffer C and eluted with buffer D, containing 50 mM Tris⅐HCl (pH 7.5), 10% (vol/vol) glycerol, 150 mM NaCl, and 250 mM imidazole.
The peak fractions were pooled and loaded on a 50-ml Amylose column (New England Biolabs). The column was washed with 100 ml of buffer E [50 mM Tris⅐HCl (pH 7.5), 5% (vol/vol) glycerol, 150 mM NaCl, and 0.5 mM EDTA] and eluted with a linear gradient of 0 -10 mM maltose in buffer E. The peak fractions were pooled and subjected to disulfide shuffling in the presence of oxidized (GSSG) and reduced (GSH) glutathione (Sigma) and DsbC purified as described in SI Methods. The shuffling reaction contained 1 mg/ml MBP-PTH1R-ECD-His 6 in 50 mM Tris⅐HCl (pH 7.5), 5% (vol/vol) glycerol, 150 mM NaCl, 0.5 mM EDTA, Ϸ3 mM maltose, 1 mM GSH, 1 mM GSSG, and DsbC at a 1:1 molar ratio between MBP-PTH1R-ECD-His 6 and DsbC. After incubation at 20°C for Ϸ20 h, the disulfide shuffling reaction mixture was applied to a Ni 2ϩ -chelating Sepharose column to remove the DsbC.
The peak fractions eluted from the column were applied to a gel filtration column followed by a QFF anion exchange column, to remove remaining misfolded MBP-PTH1R-ECD-His6. The functional protein eluted from the gel filtration column at a volume corresponding to the monomer. At this point, the protein was Ͼ95% pure as judged by SDS/PAGE and native/PAGE. The final protein was dialyzed to a storage buffer containing 50 mM Tris⅐HCl (pH 7.5), 50% (vol/vol) glycerol, 150 mM NaCl, and 1 mM EDTA and was stored as aliquots at Ϫ80°C. A yield of Ϸ25 mg was obtained from a 6-liter culture.
Binding Assays. The binding between PTH and the PTH1R ECD was determined by an AlphaScreen assay using a hexahistidine detection kit from PerkinElmer (52) . The binding mixtures, containing 40 nM N-terminally biotinylated PTH-(7-34)-NH2, 40 nM of MBP-PTH1R-ECD-His6, 15 g/ml of streptavidin-coated ''donor'' beads, and Ni-chelate-coated ''acceptor'' beads, were incubated in a buffer of 50 mM Mops (pH 7.4), 100 mM NaCl, and 0.1 mg/ml BSA for 1 h. For competition assays, 100 M unlabeled peptides were added and incubated for 1 additional h before signal recording. Details of peptide synthesis and ITC experiments are described in SI Methods.
Crystallization, Data Collection, and Structure Determination. Crystals of the purified MBP-PTH1R-ECD bound to a synthetic PTH fragment (residues [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] were grown in hanging drops containing a reservoir solution of 100 mM sodium cacodylate (pH 6.5) and 30% (vol/vol) polypropylene glycol P400 (PPG P400). Diffraction data were collected at 21-ID-D (LS-CAT) of the Advanced Photon Source at Argonne National Laboratory (Argonne, IL). The structure was solved by molecular replacement using Phaser (53) with the Protein Data Bank (PDB) coordinates 1ANF (44) and was refined with Refmac5 (54) . The statistics of data collection and the refined structure are summarized in Table S1 . Details of crystallization, data collection, and structure determination are described in SI Methods.
